On a disclosed annual basis, revenue was KRW 244 million in 2022, KRW 123 million in 2023 (down 49.4% year on year) and KRW 121 million in 2024 (down 2.0%), before jumping to KRW 3.43 billion in 2025 (up 2,736.7%). 2025 is the largest year and 2024 the smallest within 2022 to 2025.
The company attributed the 2025 revenue increase to the commercialization of its AI drug discovery platform. Operating loss was KRW 11.8 billion in 2022, KRW 12.3 billion in 2023 and KRW 14.3 billion in 2024, then narrowed to KRW 10.8 billion in 2025.
Operating margin moved from -4,833.0% in 2022 and -11,804.0% in 2024 to -313.9% in 2025. Net loss attributable to controlling shareholders widened to KRW 17.4 billion in 2025 from KRW 7.21 billion in 2024, and the disclosed net loss including non-controlling interests was also KRW 17.4 billion.
The company cited the base effect of a smaller derivative valuation gain from the prior year and a change in financing costs, including interest expense. Operating cash flow was negative in all four years, at -KRW 8.51 billion in 2022, -KRW 8.08 billion in 2023, -KRW 10.5 billion in 2024 and -KRW 10.6 billion in 2025.
On a quarterly basis, fourth-quarter 2025 sales of KRW 1.76 billion rose 286.2% from the prior quarter and accounted for more than half of full-year 2025 sales.
First-quarter 2026 sales of KRW 422 million fell 76.0% from the prior quarter, but sales then rose to KRW 449 million in the second quarter and KRW 689 million in the third, two straight quarters of growth. Operating loss widened from KRW 2.22 billion in the second quarter of 2026 to KRW 3.67 billion in the third.
Net loss attributable to controlling shareholders across the four quarters from the fourth quarter of 2025 through the third quarter of 2026 totaled KRW 14 billion. The debt ratio fell from 75.3% in 2024 to 46.4% in 2025, and total equity stood at KRW 31.8 billion at end-2025.